AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15701185 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up ultrasound at the third menstrual cycle after surgery.
Number of subjects: 47
Study 11503007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg twice daily (1 day before treatment and 3 days of concomitant administration)
Number of subjects: 16
Study 11503007 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 300 mg twice daily (3 days before treatment and 3 days of concomitant administration)
Number of subjects: 16
Study 11503007 — intervention group
Group type: COMPARATOR
Intervention: Ifosfamide alone
Number of subjects: 16
Study 9266289 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolacton 50 Heumann
Number of subjects: 24
Study 9266289 — intervention group
Group type: COMPARATOR
Intervention: Aldactone 50
Number of subjects: 24
Study 9266289 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 24
Study 9266289 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenone
Number of subjects: 24
Study 9266289 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 alpha-thiomethylspirolactone
Number of subjects: 24
Study 9266289 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone and Canrenone
Number of subjects: 24
Study 8007702 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil - CMF)
Number of subjects: 3427
Study 8007702 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3427
Study 3527011 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of almitrine bismesylate twice daily
Number of subjects: 67
Study 3527011 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of almitrine bismesylate twice daily
Number of subjects: 67
Study 3527011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 31738382 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive testing with coronary computed tomographic angiography
Number of subjects: 8966
Study 31738382 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional testing
Number of subjects: 8966
Study 31738382 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 8966
Study 30301127 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa (2.5 g/day for 12 weeks)
Number of subjects: 42
Study 30301127 — intervention group
Group type: COMPARATOR
Intervention: Cocoa-free capsules (placebo)
Number of subjects: 42
Study 28988541 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg plus PQP 640 mg
Number of subjects: 437
Study 28988541 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg plus PQP 960 mg
Number of subjects: 437
Study 28988541 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg plus PQP 1440 mg
Number of subjects: 437
Study 28988541 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg plus PQP (all doses)
Number of subjects: 437
Study 28988541 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg plus PQP (in African population)
Number of subjects: 437
Study 28988541 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg plus PQP (in Vietnam)
Number of subjects: 437
Study 28988541 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg plus PQP
Number of subjects: 437
Study 26642329 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based brief alcohol primary prevention intervention (IBI)
Number of subjects: 896
Study 26642329 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 896
Study 23203216 — intervention group
Group type: EXPERIMENTAL
Intervention: HYAL group (hyaluronan-bound sperm)
Number of subjects: 802
Study 23203216 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional assessment of motility and morphology)
Number of subjects: 802
Study 21296803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of progesterone supplementation on the 16th day post-ET (study group, n = 100)
Number of subjects: 200
Study 21296803 — intervention group
Group type: COMPARATOR
Intervention: Continuation of progesterone supplementation until 7 weeks of gestation (control group, n = 100)
Number of subjects: 200
Study 21296803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of progesterone supplementation (study group)
Number of subjects: 200
Study 21296803 — intervention group
Group type: COMPARATOR
Intervention: Continuation of progesterone supplementation (control group)
Number of subjects: 200
Study 18465335 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conserving surgery (BCS)
Number of subjects: 1154
Study 18465335 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy (M)
Number of subjects: 1154
Study 16531905 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA (5 g.d(‐1))
Number of subjects: 76
Study 12975188 — intervention group
Group type: EXPERIMENTAL
Intervention: Early weightbearing with ankle in plantigrade position
Number of subjects: 0
Study 12975188 — intervention group
Group type: COMPARATOR
Intervention: Standard immobilization with ankle in full equinus
Number of subjects: 0
Study 12534358 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg (5000 IU) r‐hCG subcutaneously twice each week for 3 months (n=20)
Number of subjects: 40
Study 12534358 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections for 3 months (n=20)
Number of subjects: 40
Study 10390407 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (120 micrograms)
Number of subjects: 0
Study 10390407 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (250 micrograms)
Number of subjects: 0
Study 9484091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser treatment (Group A) with varying power levels (0.8 W, 1.0 W, 1.2 W, 1.5 W)
Number of subjects: 14
Study 9484091 — intervention group
Group type: COMPARATOR
Intervention: Conventional scaling alone (Group B)
Number of subjects: 14
Study 9484091 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment at different power levels
Number of subjects: 14
Study 1862585 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐Chek (Du Pont)
Number of subjects: 30
Study 1862585 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1/HIV‐2 TestPack (Abbott)
Number of subjects: 30
Study 1862585 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombigen (BioScience)
Number of subjects: 30
Study 6348378 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of methylprednisolone (MP)
Number of subjects: 86
Study 6348378 — intervention group
Group type: COMPARATOR
Intervention: Low-dose regimen of methylprednisolone (MP)
Number of subjects: 86
Study 31575537 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated GP care for persistent physical symptoms; details on dosage and duration not available.
Number of subjects: 0
Study 31575537 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list); details on dosage and duration not available.
Number of subjects: 0
Study 30005705 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex multiple risk behaviour intervention
Number of subjects: 26
Study 30005705 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study 27406589 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose bevacizumab (5 mg/kg) plus lomustine (90 mg/m²)
Number of subjects: 71
Study 27406589 — intervention group
Group type: COMPARATOR
Intervention: Standard dose bevacizumab (10 mg/kg)
Number of subjects: 71
Study 24820191 — intervention group
Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons (STS) score
Number of subjects: 2466
Study 24820191 — intervention group
Group type: EXPERIMENTAL
Intervention: logistic European System for Cardiac Operative Risk Evaluation (LES) score
Number of subjects: 2466
Study 22895694 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Number of subjects: 50
Study 22895694 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 50
Study 20592630 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (two cycles of cisplatin and vinorelbine followed by radiotherapy together with third cycle)
Number of subjects: 99
Study 20592630 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (30 Gy/10 fractions)
Number of subjects: 99
Study 19845074 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil sustained release (SR) + Trandolapril (Ve + Tr)
Number of subjects: 1170
Study 19845074 — intervention group
Group type: COMPARATOR
Intervention: Atenolol + Hydrochlorothiazide (At + HCTZ)
Number of subjects: 1170
Study 15957690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine
Number of subjects: 19
Study 11852292 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg/d for 1 week, then 20 mg/d) in depressed patients (n = 18) and half of the nondepressed subgroup (n = 14)
Number of subjects: 46
Study 11852292 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg/d for 1 week, then 20 mg/d)
Number of subjects: 46
Study 11852292 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram combined with levodopa
Number of subjects: 46
Study 9787148 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) with autologous stem cell support (early HDT group, n = 91)
Number of subjects: 202
Study 9787148 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy (CCT) regimen (late HDT group, n = 94)
Number of subjects: 202
Study 9787148 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) with autologous stem cell support (early HDT group)
Number of subjects: 202
Study 9787148 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy (CCT) regimen (late HDT group)
Number of subjects: 202
Study 7674688 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers and beta-blockers for rate control
Number of subjects: 0
Study 7674688 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose anticoagulation therapy
Number of subjects: 0
Study 7674688 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy
Number of subjects: 0
Study 7674688 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 0
Study 7674688 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone in low doses
Number of subjects: 0
Study 7674688 — intervention group
Group type: EXPERIMENTAL
Intervention: No anticoagulation or antiplatelet therapy
Number of subjects: 0
Study 2379359 — intervention group
Group type: EXPERIMENTAL
Intervention: Static reconstruction (Group S)
Number of subjects: 82
Study 2379359 — intervention group
Group type: COMPARATOR
Intervention: Dynamic reconstruction (Group D)
Number of subjects: 82
Study 581950 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg digoxin orally
Number of subjects: 10
Study 581950 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg digoxin i.v.
Number of subjects: 10
Study 29455421 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 544
Study 27851668 — intervention group
Group type: EXPERIMENTAL
Intervention: RTI (Resistance Training with Instability)
Number of subjects: 39
Study 27851668 — intervention group
Group type: COMPARATOR
Intervention: RT (Resistance Training)
Number of subjects: 39
Study 26666738 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative infusion of branched-chain amino acids (BCAA) solution (N = 20)
Number of subjects: 61
Study 26666738 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative infusion of amino acids (AA) solution (N = 21)
Number of subjects: 61
Study 26666738 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) (N = 20)
Number of subjects: 61
Study 24459689 — intervention group
Group type: EXPERIMENTAL
Intervention: SHED‐IT weight loss program
Number of subjects: 145
Study 21324747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic morphologically selected sperm injection (IMSI)
Number of subjects: 168
Study 21324747 — intervention group
Group type: COMPARATOR
Intervention: Conventional intracytoplasmic sperm injection (ICSI)
Number of subjects: 168
Study 21324747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic morphologically selected sperm injection (IMSI) in severe male factor patients
Number of subjects: 168
Study 21324747 — intervention group
Group type: COMPARATOR
Intervention: Conventional intracytoplasmic sperm injection (ICSI) in severe male factor patients
Number of subjects: 168
Study 18292452 — intervention group
Group type: COMPARATOR
Intervention: Preoperative PVB with 20 mL of ropivacaine 0.5%
Number of subjects: 48
Study 18292452 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ropivacaine 0.5% infusion (CRI) at a 2 mL/h rate for 24 h
Number of subjects: 48
Study 16502745 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyriax physiotherapy
Number of subjects: 75
Study 16502745 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise programme
Number of subjects: 75
Study 16502745 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarized polychromatic non‐coherent light (Bioptron light)
Number of subjects: 75
Study 14637276 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment supplemented with antioxidants for 12 weeks
Number of subjects: 40
Study 14637276 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment for 12 weeks
Number of subjects: 40
Study 11712326 — intervention group
Group type: COMPARATOR
Intervention: EGG recording during fasting state
Number of subjects: 10
Study 11712326 — intervention group
Group type: COMPARATOR
Intervention: EGG recording after a standard meal
Number of subjects: 10
Study 11712326 — intervention group
Group type: COMPARATOR
Intervention: 24-hours pH-metry
Number of subjects: 10
Study 11712326 — intervention group
Group type: COMPARATOR
Intervention: De Meester and Johnson scoring
Number of subjects: 10
Study 11712326 — intervention group
Group type: COMPARATOR
Intervention: Correlation analysis
Number of subjects: 10
Study 9223116 — intervention group
Group type: EXPERIMENTAL
Intervention: T lymphocytes stimulated by anti-CD3 mAb
Number of subjects: 40
Study 9223116 — intervention group
Group type: EXPERIMENTAL
Intervention: T lymphocytes stimulated by phorbol myristate acetate (PMA)
Number of subjects: 40
Study 9223116 — intervention group
Group type: EXPERIMENTAL
Intervention: T lymphocytes stimulated by anti-CD3 mAb and costimulated by CD28 mAb
Number of subjects: 40
Study 9223116 — intervention group
Group type: EXPERIMENTAL
Intervention: T lymphocytes stimulated by PMA and costimulated by CD28 mAb
Number of subjects: 40
Study 7956400 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with etoposide (100 mg/m2), cisplatin (25 mg/m2), ifosfamide (1.5 g/m2), and mesna (1.8 g/m2) for 4 days, 3 cycles every 21 days
Number of subjects: 33
Study 3314173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine retard
Number of subjects: 0
Study 3314173 — intervention group
Group type: COMPARATOR
Intervention: Non-retard cimetidine preparation
Number of subjects: 0
Study 2179096 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol (dosage to reduce resting pulse rate by 25%)
Number of subjects: 108
Study 2179096 — intervention group
Group type: COMPARATOR
Intervention: Long-term injection sclerotherapy
Number of subjects: 108
Study 2179096 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (propranolol and sclerotherapy)
Number of subjects: 108
Study 1097148 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 20 mg + CBN 40 mg
Number of subjects: 0
Study 1097148 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 20 mg + CBD 40 mg
Number of subjects: 0
Study 1097148 — intervention group
Group type: COMPARATOR
Intervention: THC 20 mg + Placebo
Number of subjects: 0
Study 30601349 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy device
Number of subjects: 200
Study 30601349 — intervention group
Group type: COMPARATOR
Intervention: Handheld computer
Number of subjects: 200
Study 31866256 — intervention group
Group type: EXPERIMENTAL
Intervention: In-class delivery of feeding content and nutrition education
Number of subjects: 540
Study 31866256 — intervention group
Group type: EXPERIMENTAL
Intervention: Online delivery of feeding content and in‐class delivery of nutrition education
Number of subjects: 540
Study 31866256 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education only
Number of subjects: 540
Study 30767409 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 g of frozen red raspberries (RR-125)
Number of subjects: 32
Study 30767409 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 g of frozen red raspberries (RR-250)
Number of subjects: 32
Study 30767409 — intervention group
Group type: COMPARATOR
Intervention: 0 g of frozen red raspberries (Control)
Number of subjects: 32
Study 28376877 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine
Number of subjects: 360
Study 28376877 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular aripiprazole
Number of subjects: 360
Study 25832312 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg every 2 weeks
Number of subjects: 325
Study 25832312 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg every 4 weeks
Number of subjects: 325
Study 25832312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 25832312 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg every 2 weeks and CZP 400 mg every 4 weeks
Number of subjects: 325
Study 23731852 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrupedal head position
Number of subjects: 106
Study 23731852 — intervention group
Group type: COMPARATOR
Intervention: Non-quadrupedal head position
Number of subjects: 106
Study 21832988 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg) + Active cognitive bias training
Number of subjects: 62
Study 21832988 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (20 mg) + Control cognitive bias training
Number of subjects: 62
Study 21832988 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Active cognitive bias training
Number of subjects: 62
Study 21832988 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Control cognitive bias training
Number of subjects: 62
Study 19627023 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg
Number of subjects: 200
Study 19627023 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg
Number of subjects: 200
Study 19627023 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg plus Lidocaine
Number of subjects: 200
Study 19627023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 200
Study 19627023 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron/lidocaine combination
Number of subjects: 200
Study 17658696 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Number of subjects: 335
Study 17658696 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Expectancy Challenge (AEC)
Number of subjects: 335
Study 17658696 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and AEC (combined)
Number of subjects: 335
Study 17658696 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (control)
Number of subjects: 335
Study 14511967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (booklet about postnatal depression, prenatal screening, discussion, alert letter)
Number of subjects: 509
Study 14511967 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 509
Study 10444050 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel contact lenses with varying water content
Number of subjects: 2
Study 10444050 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA Group IV lenses
Number of subjects: 2
Study 8542123 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan evaluation
Number of subjects: 133
Study 8542123 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic bronchoscopy (FOB)
Number of subjects: 133
Study 8542123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox's hazard model
Number of subjects: 133
Study 8542123 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 133
Study 1676524 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg remoxipride
Number of subjects: 12
Study 1676524 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sulpiride
Number of subjects: 12
Study 1676524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6134048 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion diets and provocation tests
Number of subjects: 23
Study 6134048 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with confirmed food hypersensitivity
Number of subjects: 23
Study 6134048 — intervention group
Group type: COMPARATOR
Intervention: Patients whose belief in food allergy could not be confirmed
Number of subjects: 23
Study 30947107 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity functional anaerobic and progressive resistance training of the lower limbs (n = 8)
Number of subjects: 17
Study 30947107 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n = 9)
Number of subjects: 17
Study 28492790 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBNP (0.005 µg kg‐1 min‐1 for 72 hours)
Number of subjects: 48
Study 28492790 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy only)
Number of subjects: 48
Study 26199182 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day DEX
Number of subjects: 116
Study 26199182 — intervention group
Group type: COMPARATOR
Intervention: 1-day DEX
Number of subjects: 116
Study 23621906 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood injection
Number of subjects: 50
Study 23621906 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection
Number of subjects: 50
Study 22082239 — intervention group
Group type: COMPARATOR
Intervention: Usual care (quarterly PCP visits with education about weight management)
Number of subjects: 390
Study 22082239 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief lifestyle counseling (quarterly PCP visits + brief monthly sessions with lifestyle coaches)
Number of subjects: 390
Study 22082239 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced brief lifestyle counseling (same as brief lifestyle counseling + meal replacements or weight-loss medication)
Number of subjects: 390